Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
Posts
- Category: important (continued)
- Roche announces details of its 'pivotal' huntingtin-lowering study
- Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms
- Scientists hunt down origin of Huntington's disease in the brain
- Scripps Florida Scientists Uncover Major Factor in Development of Huntington’s Disease
- SIGNAL: A new investigational approach to early treatment of Huntington’s disease
- Sleep, cilia and HD
- Sorry folks, the PRIDE-HD trial did NOT show that Pridopidine slows the progression of Huntington's disease
- Stanford study identifies new biomarkers for Huntington's disease
- Statement of the EHDN Executive Committee about the PRIDE-HD trial
- Structural Genomics Consortium and CHDI Foundation announce open-access collaboration to discover new drug targets for Huntington’s disease
- Structure of brain plaques in Huntington's disease described
- Study discovers novel therapeutic targets for Huntington's disease
- Study Suggests Potential Therapy for Huntington’s Disease
- SVELATA LA GENESI DEI NEURONI DELLO STRIATO
- Swapping Sick for Healthy Brain Cells Slows Huntington’s Disease
- Synthetic gene circuits pump up cell signals
- Synthetic Oil Drug May Bring Promise for Huntington’s Disease
- TAU DISCOVERS THAT PROTEIN CLUSTERS IMPLICATED IN NEURODEGENERATIVE DISEASES ACTUALLY SERVE TO PROTECT BRAIN CELLS
- Tetrabenazine in the therapy of choreic movements: the point of view of Jo Jankovic
- Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top-Line Data from the First Pivotal Study of Investigational Treatment for Patients with Tardive Dyskinesia
- Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO™ (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA Neurology
- Teva Announces Breakthrough Therapy Designation for SD-809 Granted by FDA for the Treatment of Tardive Dyskinesia
- Teva Announces FDA Acceptance of NDA for SD-809 for Treatment in Huntington Disease
- Teva Announces FDA Acceptance of Resubmitted New Drug Application for SD-809 for Treatment of Chorea Associated with Huntington Disease
- Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease
- The Abstracts for the 2013 World Congress Huntington’s Disease 15-18 Sept, Rio de Janeiro, Brazil
- The best news for the Huntington's disease community since the discovery of the gene: Ionis trial data revealed, Roche confirms jump to Phase 3
- The Lancet Neurology publishes Prana’s Huntington’s Disease Trial
- TSRI Scientists Find Drug That Helps Huntington's Disease-Afflicted Mice-and Their Offspring
- Turning skin cells into brain cells: a Huntington's disease research breakthrough?
- UB researchers discovered new applications of the drug fingolimod to improve cognitive deficits in Huntington's disease
- UBC scientists develop test to measure effectiveness of treatments for Huntington’s disease
- UCI team finds method to reduce accumulation of damaging Huntington’s disease protein
- UCI team gets $5 million to create stem cell treatment for Huntington’s disease
- UCI-led study demonstrates how Huntington’s disease proteins spread from cell to cell
- UCLA researchers identify molecular ‘switch’ that causes Huntington’s disease–like symptoms in mice
- UF Health researchers identify novel proteins linked to Huntington’s disease
- Uguale, ma diversa: la Malattia di Huntington Giovanile -
- Uguale, ma molto diversa: la Malattia di Huntington Giovanile
- uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington’s Disease
- uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach
- uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference
- uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- University of Toronto Researcher First to Open Lab Notes in Real Time
- Unlocking a Mystery of Human Disease . . . in Space
- Update confirms Huntington's disease 'gene silencing' trial on track
- UW Receives Patent for Huntington’s Disease Treatment
- UW Scientists Find Excess Mitochondrial Iron, Huntington’s Disease Link
- Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease
- Vaccinex, Inc. announces the initiation of a Phase 2 clinical trial of its investigational VX15/2503 antibody in Huntington’s disease (the SIGNAL trial)
Plugin by dagondesign.com
